

A Systematic Review of the Quality of Liver Biopsy Specimens

Evangelos Cholongitas, MD,¹ Marco Senzolo, MD,¹ Richard Standish, MD,² Laura Marelli, MD,¹ Alberto Quaglia, MD,² David Patch, MD,¹ Amar P. Dhillon, MD² and Andrew Kenneth Burroughs, MD¹

Key Words: Liver biopsy; Percutaneous liver biopsy; Transjugular liver biopsy; Length; Portal tract

DOI: 10.1309/W3XCNT4HKFBN2G0B

Abstract

Characteristics for an optimal liver biopsy specimen were recently defined as 20 to 25 mm long and/or containing more than 11 complete portal tracts (CPTs). A systematic review of percutaneous liver biopsy (PLB) and transjugular liver biopsy (TJLB) series yielded only 32 PLB studies in which these characteristics were evaluated: mean \pm SD length, 17.7 \pm 5.8 mm and number of CPTs, 7.5 \pm 3.4; and 15 TJLB studies: mean \pm SD length, 13.5 \pm 4.5 mm and number of CPTs, 6.8 \pm 2.3. Studies of sampling heterogeneity and intraobserver and interobserver variability also used inadequate specimens by present standards. Only 11 (5.3%) of 207 therapeutic studies for chronic hepatitis B and C documented length and/or number of CPTs. Of the current 12 studies evaluating noninvasive fibrosis tests, only 8 documented length or number of CPTs, and only 1 documented length and number of CPTs. New studies are needed based on adequate liver biopsy samples to provide reliable estimation of grading and staging in chronic liver disease.

Liver biopsy (LB) is an important diagnostic tool and helps make therapeutic decisions in acute and chronic liver disease.¹ Histopathologic examination is the “gold standard” in chronic hepatitis C (CHC) for assessing changes after antiviral therapy² and is considered mandatory for grading (necroinflammatory activity) and staging (fibrosis) in most patients,^{3,4} including patients with persistently normal aminotransferase values,⁵⁻⁸ and also for evaluating steatosis, all histologic features that affect the natural history and therapeutic outcome.⁹⁻¹³ In chronic hepatitis B (CHB), the same applies.¹⁴

An LB specimen consists of approximately 1/50,000 of the hepatic mass, but it is considered reasonably representative of the whole liver.¹⁵ Several studies have evaluated the following: (1) the optimal size of the LB specimen necessary for accurate evaluation of diffuse liver disease, (2) whether heterogeneity of liver disease represents a real problem in clinical practice, and (3) whether intraobserver and interobserver variation significantly affect LB interpretation and which liver disease severity scoring system is the most reliable.

The status of LB is being challenged by noninvasive tests for the evaluation of fibrosis and its value questioned owing to variable specimen quality. Recent studies have evaluated optimal length^{16,17} and number of portal tracts¹⁷ for accurate grading and staging in chronic viral hepatitis. Thus, there has been further emphasis on the quality of LB leading to an accurate interpretation.

Percutaneous LB (PLB) and transjugular LB (TJLB) are the 2 main techniques. Laparoscopic biopsies and biopsies during laparotomy are more invasive¹⁸; endoscopic ultrasound-guided biopsy¹⁹ has not been established as an alternative method. The needles are considered large when the external diameter is 1.0 mm or more (14-19 gauge) and thin when

it is less than 1.0 mm (≥ 20 gauge). Suction (Menghini) and cutting (Tru-Cut) needles are used most often.

PLB is the most common procedure and lasts just a few seconds; it is performed under local anesthesia with lidocaine while the patient holds his or her breath after expiration.^{20,21} Although compared with Menghini needles, Tru-Cut needles usually produce a less fragmented sample,^{22,23} there are conflicting results about their relative safety.^{18,23} Major and minor complications occur in up to 6% with PLB, and 0.04% to 0.11% can be life threatening^{15,24,25} related to the following: (1) technical factors, including experience of operators,²⁶⁻²⁸ larger needles,^{21,22} more than 1 pass,^{23,28-32} and, possibly, not using ultrasonography before or during LB,^{1,28,30,33-38} and (2) impaired coagulation beyond current safe limits.²⁴ The most important complication is bleeding.

TJLB has been used since 1970 and is an alternative and safe method in high-risk patients, ie, massive obesity, gross ascites, severe coagulopathy, or previous failure of PLB. TJLB has the advantage that the Glisson capsule is not breached except as a procedural complication from within the liver. Bleeding, therefore, is extremely rare.^{1,15,18,27} Hepatic venous pressure gradient measurements^{18,27} and carbon dioxide portography can be performed concomitantly.¹ Initially, TJLB was an aspiration technique, resulting in excessive fragmentation and small specimens, making diagnosis difficult.^{39,40} However, the Tru-Cut TJLB needle has improved the technique without increasing complications.⁴¹⁻⁴³ Few series report deaths: mortality is 0.5% or less,⁴⁴ and complications range from 0.1% to 20% and include abdominal pain, cardiac arrhythmias, capsular perforation, and, rarely, intraperitoneal hemorrhage.^{1,41} Multiple passes with the TJLB needle have not led to increased complication rates.^{43,45}

Specimen Size and Histologic Evaluation of Grading and Staging

Holund et al⁴⁶ first studied diagnostic reproducibility relative to specimen size in 100 selected LB specimens that were 25 mm or longer and 1 mm or wider in patients with acute or chronic hepatitis or cirrhosis. Part of the histologic slide was covered with opaque paper to evaluate the influence of various "artificial lengths." The conclusion was that an LB specimen 5 mm long or longer was adequate for diagnosing acute hepatitis but inadequate for chronic hepatitis or cirrhosis. Subsequently, the same group⁴⁷ focused on chronic hepatitis, using the same selection criteria (16-gauge Menghini needles with an external diameter of 1.65 mm). Specimens of 15 mm or more were necessary for an accurate diagnosis of chronic aggressive hepatitis.

Another study using the same methods in patients with CHC included 100 PLB specimens that were 20 mm or longer; the needle used was not described.⁴⁸ The METAVIR scoring system was assessed in different lengths: 5, 10, 15,

and 20 mm or longer, with the latter as the reference standard for concordance.⁴⁹ A 10-mm length was adequate for reliable assessment of necroinflammatory activity and fibrosis (weighted κ , 0.81 and 0.85, respectively).

Colloredo et al¹⁷ evaluated 161 LB specimens from patients with CHC and CHB using the Ishak scoring system, excluding biopsy specimens less than 3 cm long but none based on width. Initially, each sample was scored 3 times by evaluating the entire specimen (≥ 3 cm), the first 1.5 cm, and the first 1.0 cm. Then, the width was reduced to 1.0 mm by using an optical device, and each biopsy specimen was rescored, blindly, twice by evaluating the entire length (≥ 3 cm) and the first 1.5 cm. The reduction in length led to a significant decrease in number of CPTs and underestimation of necroinflammatory activity. Thus, severe grade was diagnosed in 11.8% of LB specimens that were 3 cm or longer but only 0.6% of LB specimens that were 1.5 cm long (both were 1.4 mm wide), and severe stage was diagnosed in 11.2% of LB specimens 3 cm or longer but in only 3.1% of LB specimens 3 cm or longer but 1 mm wide. A specimen 20 mm or longer and/or containing 11 or more CPTs was necessary for reliable assessment of grading and staging in chronic viral hepatitis. These criteria have been adopted rapidly as optimal standards. However, it is clear that more than 50% were a priori inadequate because 194 were excluded from 355 LB specimens. Second, whether a 16-gauge needle (external diameter, 1.65 mm) results in a constant width of 1.4 mm needs to be questioned because other studies using larger needles (14 gauge; external diameter, 2.1 mm) describe a mean \pm SD width of 0.9 ± 0.3 mm.⁵⁰ In practice, biopsy width is not uniform because of variable tissue shrinkage and because the plane of section cannot always be through the maximum diameter of the biopsy cylinder. Third, the method of changing the width by covering with a straight-edged mask cannot be accurate; most histologic sections do not lie in straight lines.

Bedossa et al¹⁶ evaluated the adequacy of LB samples obtained at least 3 cm from the tumor by using image analysis of 17 surgical specimens following resection for hepatocellular carcinoma in patients with CHC. They derived 10,659 virtual liver samples varying from 2.5 to 200 mm in length and a constant 1.2 mm width. The image analysis of fibrosis was converted to the METAVIR scoring system (the reference METAVIR stage was based on the whole sample, at least 2×3 cm). Accurate evaluation of fibrosis was achieved in only 65% of 15-mm-long and 75% of 25-mm virtual samples, with no significant improvement with longer samples. The conclusion was that a specimen 25 mm long was the minimum length for reliable staging.

We aimed to evaluate the literature in terms of size and quality of PLB and TJLB specimens in relation to the recently proposed minimum requirements for the assessment of

chronic viral hepatitis and heterogeneity and intraobserver and interobserver variation, particularly with thin-needle LB, using the current histologic scoring systems for grading and staging in CHC and CHB and to examine these variables in clinical trials of antiviral therapy and in studies assessing noninvasive markers of fibrosis.

Materials and Methods

We performed a systematic review of the length and number of CPTs in published series of PLBs using a MEDLINE search (English/non-English) and the following key words: “percutaneous liver biopsy,” “needle,” “Menghini,” “Tru-Cut,” “sample size,” and “length.” Published abstracts from European and American gastroenterology and hepatology conferences during the previous 10 years also were reviewed. Reference lists from these studies were hand searched to identify further relevant articles. A total of 162 studies were evaluated, but only 32 (27 full articles and 5 abstracts) had information about length and/or number of CPTs.^{22,24,33,35,36,44,50-75} The following variables were extracted: number of patients, number of PLBs performed, type of needle (Menghini or Tru-Cut), size of needle (diameter), and whether the procedure was ultrasound-guided or “blind.”

All data were analyzed by using the statistical package SPSS (version 10.0, SPSS, Chicago, IL). The χ^2 test was used to compare qualitative variables and the *t* test and Mann-Whitney test to compare quantitative variables, as appropriate. Quantitative variables with normal distribution were expressed as the mean \pm 1 SD and with skewed distribution as the median (range). The significance level was set at a *P* value of .05 or less (2-sided).

Results

Systematic Review of Length and Number of CPTs Obtained With PLB

All 32 studies reported length but only 12 reported the number of CPTs (Table 1), 5 did not report mean and range,^{22,52,53,55,61} but just categories, eg, longer or longer than a certain length. Fragmentation was described in 8 studies, but in only 4 was the mean number of fragments given.^{35,50,54,59} There were 8,746 patients from whom 10,027 PLB specimens were obtained. The needle size was from 14 to 19 gauge (median, 16 gauge) (Table 1). There were 4,481 Menghini needle biopsies, 4,134 Tru-Cut needle biopsies, and 1,412 of unknown type. The mean \pm SD length and number of CPTs were 17.7 \pm 5.8 mm and 7.5 \pm 3.4 mm, respectively. The correlation between length and CPTs was poor (Spearman *r* = 0.45; *P* = .04). PLB specimens obtained during the 1996-2005

period compared with those obtained before 1996 were significantly longer (19.8 vs 15.7 mm; *P* = .033) and were obtained more frequently with ultrasound guidance (9 vs 2 studies; *P* = .001) using smaller needles (18 or 19 gauge; 6 vs 2 studies; *P* = .023). The Menghini needle yielded significantly longer samples (19.9 \pm 6.6 mm) compared with the Tru-Cut needle (14.3 \pm 3.2 mm; *P* = .016), but without a significant difference in the number of CPTs (7.3 vs 6.9; *P* = .8) (Table 2). Only 1 study using the Tru-Cut needle⁷⁰ documented the range in length, so it was not possible to assess whether there was less variability in length with the Tru-Cut than with the Menghini needle.

Because the Tru-Cut needle provides a maximum length of sample determined by the notch in the needle shaft (usually 20-25 mm; compared with the Menghini in which the length depends on the force of aspiration and operator experience), this could explain the longer samples obtained with the Menghini. Another reason could be that more passes were performed with the Menghini. However, 16 of 32 studies that gave such information showed that more than 1 pass was performed in 108 (3.1%) of 3,535 biopsies using the Menghini compared with 199 (12.1%) of 1,646 biopsies using the Tru-Cut.

Ultrasound Guidance

A total of 5,392 specimens from ultrasound-guided procedures and 1,369 specimens from blind biopsy procedures were analyzed. Specimens from ultrasound-guided biopsies were longer than specimens from blind biopsy procedures (20.5 vs 14.4 mm; *P* = .021), possibly because ultrasound guidance gives rise to greater confidence in performing a biopsy. However, ultrasound-guided biopsy specimens did not contain significantly more CPTs than specimens from blind biopsy procedures (8.3 vs 5.3; *P* = .13). Specimens obtained using the Menghini needle and ultrasound guidance were significantly longer than specimens obtained with the Tru-Cut and ultrasound guidance (24.4 vs 13.6 mm; *P* = .017) and specimens obtained “blindly” using the Menghini (15.8 mm; *P* = .017) (Table 2). There was no significant difference in the length of specimens obtained with the Tru-Cut needle with ultrasound guidance vs blindly.

Center Experience

We assumed that larger studies would be published by more experienced operators. LB samples were longer in studies with 100 or more PLBs than in those with fewer than 100 PLBs (20.4 mm vs 16 mm; *P* = .026). However, this difference was not significant for the number of CPTs (8 vs 7.3; *P* = .7). Specimens obtained with Menghini needles were significantly longer in studies with 100 or more PLBs than in those with fewer than 100 PLBs (24 vs 16.1 mm; *P* = .005), in contrast with studies in which Tru-Cut needles were used

Table 1
Systematic Review of 32 Studies Documenting Specimen Length and Number of Complete Portal Tracts Obtained With Standard Percutaneous Liver Biopsy

Study	No. of Patients	Type of Needle*		Guidance		Mean Length (mm) [†]	Mean No. of Portal Tracts [‡]
		Tru-Cut	Menghini	B	US		
Gilmore et al ^{22†}	1,500	990	510	930	570	<10 mm: M, 4.9%; T, 4.6%	NR
Gunneson et al ²⁴	708	NR	1,086 (15 G)	NR	1,086	32	NR
Lindor et al ³³	836	NR	NR	NR	NR	B, 16; US, 17	NR
Papini et al ³⁶	200	NR	200	100 (16 G)	100 (14 G)	B, 22; US, 28	NR
Crawford et al ⁵⁰	16	NR	16 (14 G)	NR	NR	18	8
Farrell et al ³⁵	166	201 (15/18 G)	NR	91	110	B, 16.2; US, 15	B, 7.8; US, 6.3
Gaiani et al ⁵¹	212	NR	212 (18 G)	NR	212	29	15 [§]
ter Borg et al ^{52‡}	184	184 (14 G)	NR	NR	NR	70% <15	NR
Angelucci et al ^{53‡}	501	1,184 (14 G)	NR	NR	1,184	NR	81% ≥3
Hopper et al ⁵⁴	10	28 (14 G)	52 (16-18 G)	NR	NR	M, 8.4-9.9 mm ^{2¶} ; T, 7.85 mm ^{2¶}	M, 3.9-4.5; T, 3.96
Colombo et al ^{55‡}	1,179	569 (14 G)	610 (16 G)	NR	NR	<10 mm: M, 12.4%; T, 3.6%	NR
Rocken et al ⁵⁶	79	NR	79 (17 G)	NR	79	25.3	9.7
Brunetti et al ⁵⁷	149	NR	149 (18 G)	NR	149	21.2	NR
Petz et al ⁵⁸	100	NR	41 (17 G)	NR	100	25.5	NR
Goldner ⁵⁹	3	15 (14 G)	30 (16/17 G)	NR	NR	M, 11.5; T, 16.4	NR
Chau et al ⁶⁰	50	NR	NR	NR	NR	18	11
McAfee et al ⁴⁴	50	NR	NR	NR	NR	22	NR
Vargas-Tank et al ^{61#}	66	66	132	NR	NR	≥5 mm: M, 46%; T, 94%	NR
Torp-Pedersen et al ⁶²	77	NR	77 (19 G)	77	NR	17	NR
Caturelli et al ⁶³	753	NR	753 (18 G)	NR	753	27.8	NR
Chevallier et al ⁶⁴	600	600 (18 G)	NR	NR	600	9.9	5.7
Flamm et al ⁶⁵	74	NR	NR	NR	NR	12.3	NR
Siddique et al ⁶⁶	30	NR	30 (15 G)	NR	NR	16.5	4.5
Kim et al ⁶⁷	304	NR	NR	171	304	B, 11; US, 16.2	NR
Bateson et al ⁶⁸	77	41 (14 G)	36 (15 G)	NR	NR	M, 20.7; T, 15	NR
Meng et al ⁶⁹	277	NR	277 (15 G)	NR	NR	15	NR
Maharaj et al ⁷⁰	40	40	NR	NR	NR	16.3	NR
Gurakar et al ⁷¹	76	76 (14/15 G)	NR	NR	NR	21 (14 G); 14 (15 G)	5.2 (14 G); 6 (15 G)
Spirchez et al ⁷²	145	78 (18 G)	67 (18 G)	NR	145	M, 12.6; T, 16	M, 7.2; T, 8.1
Regan et al ⁷³	98	NR	NR	NR	NR	19.1 mm ^{2¶}	5.2
Judmaier et al ⁷⁴	136	62	74	NR	NR	M, 8; T, 12	M, 6; T, 16
Steadman et al ⁷⁵	50	NR	50	NR	NR	15.9 mm ^{2¶}	NR

B, blind; NR, not reported; US, ultrasound.

[†] Data are given as number of liver biopsy specimens; when reported, the needle gauge (G) is given in parentheses. Translation of gauge to external diameter of needle (mm) is as follows: 14 G = 2.1; 15 G = 1.83; 16 G = 1.65; 17 G = 1.47; 18 G = 1.24; and 19 G = 1.06.

[‡] When reported the type of needle (M, Menghini; T, Tru-Cut) and relevant data are given.

[§] Expression of length and/or number of portal tracts as a percentage more than a specific level.

^{||} Inaccurate measurement (by assumption of study authors).

[#] Cadavers.

[¶] Expression of size as surface area (mm²).

and there were more or fewer than 100 PLBs (12.3 vs 14.8 mm, respectively; $P = .27$; Table 2). In studies with fewer than 100 PLBs, ultrasound guidance did not help to obtain longer specimens (ultrasound-guided vs non-ultrasound-guided, 17.9 vs 13.6 mm; $P = .19$).

Needle Size

There was no significant difference in length (range, 16.3-20.7 mm) or number of CPTs (range, 4.6-9.7) according to needle diameter. Longer biopsy specimens (mean, 20.7 mm) containing a larger number of CPTs (mean, 9.7) were obtained by using 17-gauge needles, but these results are derived from only 3 studies (2 from the same center^{57,59} and 1 on cadavers⁵⁹; Table 1). PLB specimens obtained by 18- or 19-gauge needles

compared with smaller ones had similar mean length (18.4 vs 18.6 mm) but contained more CPTs (8.0 vs 6.0); however, this difference was not significant. The Menghini and Tru-Cut needles were compared only in studies using 14-, 15-, and 18-gauge needles. LB specimens were, on average, longer when 14-gauge Menghini (23 vs 15.5 mm; $P = .18$) or 15-gauge Menghini (21 vs 14 mm; $P = .47$) needles were used, whereas specimens obtained using 18-gauge Menghini needles were significantly longer than those obtained with 18-gauge Tru-Cut needles (26 vs 12.8 mm; $P = .012$).

Quality of LB Specimens in Trials of Antiviral Therapy

We evaluated clinical trials from 1996 to 2004 using interferon, ribavirin, lamivudine, or adefovir in 147 trials for

Table 2
Liver Biopsy Specimen Length and Number of Portal Tracts in 32 Studies Categorized by Use of Tru-Cut and Menghini Needles in PLBs and by Guidance (Ultrasound vs Blind) and Experience*

PLB	Tru-Cut	Menghini	P
Total (n = 8,615)			
Length, mm	14.3 ± 3.2	19.9 ± 6.6	.016
No. of CPTs	6.9 ± 3.6	7.3 ± 3.6	.8
Ultrasound (n = 5,392)			
Length, mm	13.6 ± 3.2	24.4 ± 5.9	.017
No. of CPTs	6.9 ± 1.6	8.4 ± 3.9	.47
Blind (n = 1,369)			
Length, mm	12 ± 2.8	15.8 ± 4.1	.5
No. of CPTs	5.6 ± 0.7	4.2 ± 0.4	.4
Experience			
Length, mm	12.3 ± 2.9	24 ± 5.7	.018
No. of CPTs	5.6 ± 1.6	9.7 (4.5-15)	.2
No experience			
Length, mm	14.8 ± 3.2	16.1 ± 5.1	.39
No. of CPTs	5.7 (4.6-16)	6.5 ± 2.1	.9

CPT, complete portal tract; PLB, percutaneous liver biopsy.
 * Experience was defined as studies with more than 100 PLBs and no experience as studies with fewer than 100 PLBs. Variables with normal distribution are expressed as mean ± 1 SD and those with a nonnormal distribution as median (range).

CHC and 60 for CHB in which the histologic grade and stage were evaluated formally. Only 8 studies documented the type and only 9 the size of the needle. Only 11 studies for CHC provided information on LB specimen quality: length in 3,⁷⁶⁻⁷⁸ number of CPTs in 6,⁷⁹⁻⁸⁴ and both in 2.^{85,86} Thus, surprisingly only 2 of 147 studies had the relevant background information to assess whether histologic assessment was based on an adequate or optimal biopsy sample. There was even less information on interobserver and intraobserver variation, which was evaluated in only 3^{79,87,88} and 2^{79,82} studies, respectively. In CHB studies, none provided information on the quality of liver biopsy specimens, and only 3 studies assessed intraobserver and interobserver variation.⁸⁹⁻⁹¹

Evaluation of Potential Heterogeneity of Liver Disease With PLB

We found 5 studies **Table 3**.^{65,66,92-94} Only 1 study had biopsy specimens of adequate length, and in the 50 patients

with CHC studied, ultrasound-guided PLB of the right lobe (28 ± 11 mm) and left lobe (25 ± 9 mm) showed no difference between grading and staging in the paired biopsy specimens.⁹⁴ In the other studies, all had significant variability: 1 did not document length,⁹² 1 had a mean length of only 12.3 mm,⁶⁵ and 2 evaluated biopsy specimens selected as 15 mm or longer, one laparoscopic⁹³ and the other PLB.⁶⁶

Intraobserver and Interobserver Variation and Scoring Systems in PLB

We found 6 studies⁹⁵⁻¹⁰⁰ **Table 4**, and only 1⁹⁶ used samples of adequate length (≥40 mm). The Scheuer system had excellent results for intraobserver and interobserver agreement, as did the Knodell system for fibrosis but not for inflammatory score.

In the other studies, 1 did not document length,⁹⁷ 3 used samples 10 mm or longer,^{95,98,100} and 1 used samples 15 mm or longer.⁹⁹ The study that included histopathologists with different levels of expertise, duration, and location of practice¹⁰⁰ and had an excellent design only used specimens 10 mm or longer, and, thus, its results may not be applicable to optimal LB specimens. In fact, agreement increased in relation to length and number of portal tracts.

Thin-Needle vs Large-Needle PLB for Assessment of Diffuse Liver Disease

Rocken et al⁵⁶ compared the Menghini thin needle, 20 and 21 gauge, with the conventional Menghini large needle, 17 gauge, in cases with no differences in indications for biopsy or histologic diagnoses. LB specimens that were Ishak stage 5 and 6 were excluded; 343 biopsy specimens were obtained from 258 patients: 17-gauge needle used by surgeons using several passes for 28 biopsies (17Gs); single-pass percutaneous for 79 biopsies using a 17-gauge needle (17Gp); and ultrasound guidance with a 20-gauge needle in 88 biopsies (20Gp) and a 21-gauge needle in 80 biopsies (21Gp). The authors found that specimens in the 20Gp group, compared with specimens in the 17Gp group, were longer (29.8 vs 25.3 mm; *P* < .05) but contained fewer

Table 3
Studies Evaluating the Heterogeneity in Grading and Staging of Chronic Hepatitis C

Study	No. of Cases	Needle Size*	Specimen Length (mm)	No. of Portal Tracts	Scoring System	Agreement†
Flamm et al ⁶⁵	74	NR	12.3 (mean)	NR	Knodell	66%
Fanning et al ⁹²	12	NR	NR	All ≥5	Ishak	Grade, 66%; stage, 75%
Regev et al ⁹³	124	16 G	All ≥15	All ≥5	Scheuer	Grade, 98.4%; stage, 92.7%
Persico et al ⁹⁴	50	18 G	All ≥15	NR	Ishak	Right vs left lobe: grade, 8.13 vs 8.06; stage, 2.16 vs 2.13
Siddique et al ⁶⁶	29	1.7 mm	All ≥15	All ≥5	Knodell	Grade, 31%; stage, 79.3%

NR, not reported.
 * Translation of gauge (G) to external diameter of needle (mm) is as follows: 16 G = 1.65; and 18 G = 1.24.
 † Defined as <2-point difference in score.

Table 4
Studies Evaluating Intraobserver and Interobserver Variation in Scoring Liver Biopsy Specimens From Patients With Chronic Liver Disease

Study	No. of Cases	Specimen Length (mm)	Needle Size	Scoring System	Interobserver Agreement (κ or κ_w)*	Intraobserver Agreement (κ or κ_w)*
METAVIR French Study Group ⁹⁵	30 CHC	≥10	NR	Knodell	Gr, 0.56; S, 0.78	Gr, 0.49; S, 0.75
Goldin et al ⁹⁶	20 CHC and CHB	≥40	NR	Knodell and Scheuer	Gr, 0.30-0.90; S, >0.70 and Gr, 0.53-0.92; S, 0.61-0.95	Gr, 0.40-0.90; S, 0.92-1.00 and Gr, 0.72-0.92; S, 0.94-0.99
Westin et al ⁹⁷	95 CHC	NR	NR	Ishak and Ishak	Gr, 0.18-0.53; S, 0.57-0.69	NR
Gronbaek et al ⁹⁸					Gr, 0.35; S, 0.51	
Rozario and Ramakrishna ⁹⁹	127 CHC and CHB	All ≥15	NR	Ishak vs METAVIR	NR	Gr, 0.627; S, 0.998
Rousselet et al ^{100†}	254 CHC and CHB	1A, median, 16; all (except 2) ≥10	1.4/1.6 mm	METAVIR	1A, Gr, 0.43; S, 0.59; 1B, Gr, 0.44; S, 0.48; 2A, Gr, 0.25; S, 0.18	NR

CHB, chronic hepatitis B; CHC, chronic hepatitis C; Gr, grade; κ_w , weighted κ ; NR, not reported; S, stage.

* A range of κ statistics refers to those obtained for single pairs of observers as documented in the specific study.

† 1A involved 4 academic pathologists; 1B, 2 academic experts (1 senior and 1 junior); and 2A, academic and nonacademic pathologists after a training period in the METAVIR scoring system.

portal tracts (6.7 vs 9.7). An insufficient sample was obtained in 4 cases in the 20Gp group, and in only 1 in the 17Gp group. The authors concluded that 20Gp could be a reliable alternative for patients with diffuse liver disease and contraindications for large-needle (eg, 17Gp) percutaneous biopsy.

Petz et al⁵⁸ examined the feasibility of thin-needle biopsy for grading and staging in chronic viral hepatitis: 59 patients underwent thin-needle biopsy (20-gauge, 0.9-mm needle) and 41 underwent large-needle biopsy (17-gauge, 1.4-mm needle). All samples were read first separately and then together by 2 independent pathologists using the Ishak scoring system. The sample was considered adequate in all but 4 thin-needle biopsies. No significant difference was found for grading and staging between thin-needle and large-needle specimens. However, in thin-needle specimens, severe fibrosis (stage 5) and cirrhosis (stage 6) tended to be underestimated. The limitations of the study were that thin-needle and large-needle samples were not paired, the biopsy procedure was neither randomized nor standardized, and there may have been a bias because there was a significantly lower platelet count in patients who had undergone thin-needle biopsy that likely represented more advanced liver disease and/or cirrhosis.

These limitations were overcome in a study in which paired thin-needle (0.8 mm) and large-needle (1.2 mm) biopsy specimens were obtained through the same puncture site from 149 consecutive patients with CHC.⁵⁷ LB samples were considered adequate if they were 10 mm or longer, contained 4 or more portal tracts, and were not too fragmented. Two hepatopathologists made a joint evaluation using the Ishak scoring system. Large-needle specimens were significantly longer than thin-needle specimens (21.2 vs 12.2 mm; $P < .001$) and less fragmented (11% vs 42%; $P < .001$) and considered

adequate more frequently (94% vs 55.7%; $P < .001$). Comparison of the 83 paired and adequate specimens showed that in thin-needle specimens, fibrosis and all 4 categories of necroinflammatory activity were underscored systematically. Finally, thin-needle biopsy resulted in understaging of cirrhosis (2 of 3 biopsy specimens with stage 5/6). Similar results were obtained when paired samples of similar length were compared and when the METAVIR and Scheuer scoring systems were used. The authors concluded that thin-needle biopsy should be avoided for grading and staging in patients with CHC.

Transjugular Liver Biopsy

Heterogeneity of liver disease and interobserver or intraobserver variation have not been evaluated in TJLB. By using the same search criteria for TJLB as for PLB, we found only 15 studies that documented the length and number of CPTs, the needle size, or number of passes (Table 5) using a Tru-Cut and/or Menghini-type needle,^{41,42,44,45,60,73,101-109} and most described only small series. Only our large series of TJLB (n = 326) detailed the number of passes (n = 3), needle size (Tru-Cut 19 gauge), length (mean, 22.5 mm), number of CPTs (mean, 8.7) and fragmentation (median, 5).¹⁰⁹ Only 1 study compared Tru-Cut (18 gauge) and Menghini-type (16 gauge) needles and found that using the Tru-Cut resulted in significantly longer specimens (12 vs 7 mm; $P < .05$).¹⁰² Overall, 1,389 TJLB specimens were evaluated (mean, 2.5 passes per patient); the mean \pm SD length was 13.5 \pm 4.5 mm (13 of 15 studies), and the mean \pm SD number of CPTs was 6.8 \pm 2.3 (6 studies) (Table 5). Quality of TJLB requires study because this method allows multiple passes (to obtain adequate samples) with far less likelihood of increasing complication rates.^{43,45}

Table 5
Systematic Review of 15 TJLB Series Reporting at Least One of the Characteristics of Length, Portal Tracts, Number of Passes, and Fragments of Liver Biopsy Specimens

Study	No. of TJLBs	Needle Type*	No. of Passes	No. of Fragments	Mean Specimen Length (mm)	Mean No. of Portal Tracts
Chau et al ⁶⁰	18	Tr (18 G)	1-3	NR	10	4
McAfee et al ⁴⁴	146	M and Tr	NR	NR	8	NR
Regan et al ⁷³	123	Tr	NR	NR	NR	5.6
Bull et al ⁴¹	193	Tr	NR	NR	18	NR
Bruzzi et al ⁴²	50	Tr (18 G)	2.2	NR	1-20 [†]	10.4
Papatheodoridis et al ⁴⁵	157	Tr	1.8	NR	14.8	NR
Sawyer et al ¹⁰¹	44	M (16 G); Tr (NR)	≤3	NR	6	NR
Choo et al ¹⁰²	711	M (16 G); Tr (18 G)	M, 2.3; Tr, 2.9	NR	M, 7; Tr, 12	NR
DiMichele et al ¹⁰³	13	Tr (19 G)	>3-5	NR	13.6	6
Kardache et al ¹⁰⁴	29	Tr (18 G)	1	NR	12	≥8 [‡]
De Hoyos et al ¹⁰⁵	52	Tr (18 G)	NR	2.5	17	6.2
Elsharkawy et al ¹⁰⁶	100	Tr [§]	NR	NR	16	NR
Gorriz et al ¹⁰⁷	77	Tr (18 G)	5.2	NR	15.2	NR
Little et al ¹⁰⁸	43	Tr (18, 19, 20 G)	2.7	NR	11 (18 G); 15 (19 G)	NR
Cholongitas et al ¹⁰⁹	326	Tr (19 G)	3	5	22.5	8.7

M, Menghini needle; NR, not reported; Tr, Tru-Cut needle; TJLB, transjugular liver biopsy.

* When the needle gauge (G) was reported, it is given in parentheses. Translation of gauge to external diameter of needle (mm) is as follows: 16 G = 1.65; 18 G = 1.24; and 19 G = 1.06.

[†] Length per core.

[‡] In 14 patients with cirrhosis.

[§] 2.2-mm needle diameter.

Histologic Assessment Without LB

LB should be performed only “if the expected benefit exceeds the small risk associated with this procedure.”¹¹⁰ There has been renewed interest in the noninvasive evaluation of diffuse liver disease. Aspartate aminotransferase (AST)–alanine aminotransferase (ALT) and AST–platelet count ratios^{111,112} have been shown to have significant correlation with the degree of liver fibrosis in patients with chronic viral hepatitis, nonalcoholic fibrotic liver disease, or alcoholic liver disease.¹¹³ A combination of age, γ -glutamyltransferase and cholesterol levels, and platelet count had a very good correlation (area under the receiver operating characteristic curve, 0.86) with liver fibrosis in patients with CHC¹¹⁴ and a score of less than 4.2 identified patients with a METAVIR stage of fibrosis of 0 or 1 with a 96% accuracy. Recently, another index using the platelet count, the AST/ALT ratio, and the international normalized ratio was compared with Ishak fibrosis scores of 5 and 6 and was found to have an area under the receiver operating characteristic curve of 0.776 (training set) and 0.808 (validation set), but only 15% of biopsy specimens were 25 mm or longer (there was no evaluation of portal tracts because cirrhosis was being evaluated, not chronic hepatitis).¹¹⁵

More complex tests, the FibroTest (Biopredictive, Paris, France; FibroSURE LabCorp, Burlington, NC) and ActiTest (Biopredictive; FibroSURE LabCorp),^{116,117} use less common serologic markers and are at least as sensitive as the Forns scale for excluding fibrosis and discriminating significant fibrosis.^{113,118} Transient elastography (FibroScan, Biopredictive; FibroSURE LabCorp) is a novel noninvasive method for the assessment of liver fibrosis.¹¹⁹ Combined with FibroTest,

FibroScan was better for discriminating severe fibrosis and cirrhosis than FibroScan or FibroTest alone.¹¹⁹ Procollagen III aminopeptide has been considered sufficient to monitor methotrexate-induced fibrosis.¹²⁰ None of these noninvasive tests is able to distinguish different stages of fibrosis, and they are considered less reliable than LB¹¹⁸; few studies have been done outside of CHC **Table 6**.^{112,114-117,119,121-126} Surprisingly, the performance of these tests was evaluated using suboptimal liver biopsy specimens (<20-25 mm long and/or containing <11 CPTs), or the quality of the biopsy was not mentioned and neither was the needle size with 2 exceptions, both of which used 16-gauge needles.^{121,125} The current FibroScan may have limited value for assessing fibrosis in overweight or obese patients.¹¹⁹

Discussion

The minimum standards for an optimal PLB^{16,17} for assessing chronic viral hepatitis require longer specimens than before (≥ 20 -25 vs ≥ 15 mm¹⁵) and more CPTs than before (≥ 11 vs ≥ 6 -8).¹⁵ In addition, in 1 study,¹⁷ 11 CPTs were not obtained when evaluating masked biopsy specimens 1 mm wide, suggesting that 1 mm is an insufficient width.

These new standards would result in less interobserver error, at least between academic and nonacademic pathologists,¹⁰⁰ which also was confirmed by Goldin et al,⁹⁶ who had less interobserver and intraobserver variation with biopsy specimens that were 40 mm or longer, ie, a large specimen. In addition, if the new standards are met, potential heterogeneity of liver disease is not significant.⁹⁴

Table 6
Studies Evaluating Liver Fibrosis With Noninvasive Tests

Study	No. of Patients	Cause of Liver Disease	Scoring System	Liver Biopsy Specimen	Needle Size*	Noninvasive Test
Wai et al, ¹¹² 2003	192	CHC	Ishak	NR	NR	APRI
Forns et al, ¹¹³ 2002	476	CHC	METAVIR	CPT, ≥ 6	NR	Age, PLT, GGT, cholesterol
Imbert-Bismut et al, ¹¹⁶ 2001	339	CHC	METAVIR	L, >10 mm	NR	FibroTest
Castera et al, ¹¹⁹ 2005	183	CHC	METAVIR	L, 17 mm (median)	NR	FibroScan, FibroTest, APRI
Poynard et al, ¹¹⁷ 2003	352	CHC	METAVIR	NR	NR	FibroTest, ActiTest
Hui et al, ¹²¹ 2005	235	CHB	Ishak and Knodell	L, ≥ 15 mm; CPT, ≥ 5	16 gauge	BMI, PLT, albumin, bilirubin
Rosenberg et al, ¹²² 2004	211	CHC	METAVIR	L, >10 mm	NR	FibroTest
Rossi et al, ¹²³ 2003	125	CHC	METAVIR	NR	NR	FibroTest
Ziol et al, ¹²⁴ 2005	327	CHC	METAVIR	CPT, ≥ 10	NR	FibroScan
Lok et al, ¹¹⁵ 2005	1,141	CHC	Ishak	15% ≥ 25 mm	NR	PLT, AST/ALT, INR
Colletta et al, ¹²⁵ 2005	40	CHC	METAVIR	Mean, 20 mm; range, 14-25 mm	16 gauge	FibroTest, FibroScan
Poynard et al, ¹²⁶ 2005	283	CHC	METAVIR	NR	NR	FibroTest, ActiTest

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CHB, chronic hepatitis B; CHC, chronic hepatitis C; CPT, complete portal tracts; GGT, γ -glutamyltransferase; INR, international normalized ratio; L, length of specimen; NR, not reported; PLT, platelet count;

* A 16-gauge needle has an external diameter of 1.65 mm.

However, more than 1 pass is likely to be needed to obtain a PLB specimen of adequate size, which has the potential to increase the complication rate, which increases with needle size and number of passes.^{28-30,32} For this reason, the clinical applicability of the histopathologic requirement for larger liver biopsy specimens has to be explored critically. A minimum requirement for a routine LB specimen to always have 11 or more CPTs could be unrealistic and dangerous for the patient on one hand; on the other hand, the realization that inadequate samples are unreliable would make LB histopathologic examination irrelevant at best and dangerous at worst.

This said, it is surprising that only 2 of 147 studies of antiviral therapy for CHC and none for CHB had details on both the length of the LB specimen and the number of CPTs. In addition, inadequate LB specimens have been used (whenever data about the quality of LB specimens was given) in studies of noninvasive markers of fibrosis, so that no study to date is sufficiently reliable to establish the validity of nonhistologic markers. Thus, the interpretation of results in all of these studies will have flaws.

In this systematic review, comprising all documented series of PLB in the literature, the LB specimens had an average length and number of portal tracts well below the published minimum sample size requirements^{16,17} in more than half the cases. How can adequate biopsy samples be obtained for reliable grading and staging of chronic liver disease?¹⁶ Rocken et al⁵⁶ showed that all methods of LB resulted in an insufficient sample size in a significant proportion of patients: 42% of PLBs with a large 17-gauge needle contained 10 or more portal tracts. Only the surgically obtained LB specimens with multiple passes provided adequate liver samples in a very high proportion of cases. Although using a thin needle allows multiple passes without increasing complications, this advantage

is overcome by its low diagnostic performance.⁵⁷ Although specimens obtained with Menghini needles are significantly longer than those obtained with Tru-Cut needles (19.5 vs 14.3 mm; $P = .01$) the number of CPTs was no different. A new Tru-Cut needle with a larger notch (at least 30 mm) may overcome this but could result in more complications.

The number of CPTs emerged as the key factor for considering the adequacy of LB specimens.^{15,17,50} However, we could not completely assess the data on CPTs because the definition of completeness was rarely stated in the relevant studies. Rocken et al,⁵⁶ for PLBs, similar to our study for TJLBs,¹⁰⁹ used the definition of Crawford et al⁵⁰ for CPTs: complete circumference with at least 2 portal structures within them. Colloredo et al¹⁷ considered CPTs as only the portal triads with complete circumference, and partial portal tracts were those incompletely represented (usually at the margin of the specimens). It is not clear whether this refers to the circumference, the number of portal structures, or both. Moreover, it is recognized that biopsy specimens obtained at the periphery of the liver more frequently contain only a hepatic arterial branch and bile duct, missing the portal vein.⁵⁰ These portal dyads with a complete circumference are CPTs in the normal liver. This may explain in part why poor correlation was documented between length and CPTs (although still statistically significant, $r = 0.45$; $P = .04$). In addition, fragmentation will reduce number of CPTs if the break occurs through them.

In contrast with the risks of PLB with multiple passes, TJLB offers the possibility of using multiple passes without increasing complications.^{28-30,127} TJLB has been considered a second-class biopsy owing to the small specimens and increased fragmentation compared with PLB. However, our review has shown that with a mean of 2.5 passes, the biopsy specimens are on average only 4.2 mm shorter compared with

PLB (13.5 mm vs 17.7 mm, respectively), and, it is important to note, contain almost the same number of CPTs (6.8 vs 7.5, respectively), which is similar to the difference between Tru-Cut and Menghini needles. Even though the Menghini needle under ultrasound guidance gave the best average length, 24.4 mm, the mean number of CPTs was only 8.4. In our center, TJLBs are always performed with 3 passes providing LB specimens with a mean length of 22.5 mm and a mean number of CPTs of 8.7 (Table 5), similar to the “best” PLB technique. Fragmentation was not excessive using the Tru-Cut technique (median fragment number, 5) and in only 5 (1.5%) of 326 were the biopsy specimens too small or fragmented to provide a diagnosis. We are now evaluating the use of 4 passes to see whether an “ideal” specimen can be obtained consistently and in most patients. Therefore, TJLB could be an alternative and safe approach to obtain samples of adequate size and a reliable assessment of liver histologic features, particularly in clinical trials.

Despite the current enthusiasm for using noninvasive tests to diagnose the degree of fibrosis, further prospective studies are needed to validate diagnostic accuracy and usefulness. However, these studies must use optimally interpreted and adequate LB specimens. The question is whether LB can be regarded as the gold standard for the staging and grading¹¹³ of diffuse liver diseases when risks of biopsy, inadequate sampling, and intraobserver and interobserver error are taken into account. If the currently proposed minimal criteria for an LB specimen (≥ 20 -25 mm long and ≥ 11 CPTs) are to be used as a gold standard, more than 1 pass using a standard PLB will be required, with more risk of complications. Our review suggests that recent improvements in TJLB techniques offer the possibility of safely obtaining ideal LB samples. These issues assume additional importance when changes in LB histopathologic features and noninvasive tests are used as endpoints in clinical trials. Studies that have been performed using inadequate biopsy specimens by present standards must be considered insufficiently reliable to guide clinicians. New studies are needed based on adequate LB samples.

From ¹Liver Transplantation and Hepatobiliary Medicine and the ²Histopathology Department, Royal Free Hospital, London, England.

Address reprint requests to Dr Burroughs: Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital, Pond St, Hampstead, London NW3 2QG, England.

References

- Burroughs AK, Dagher L. Liver biopsy. In: Classen M, Tytgat G, Lightdale C, eds. *Gastrointestinal Endoscopy*. New York, NY: Thieme New York; 2002:252-259.
- Lee SS. Indicators and predictors of response to anti-viral therapy in chronic hepatitis C. *Aliment Pharmacol Ther*. 2003;17:611-621.
- Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. *Hepatology*. 2004;39:1147-1171.
- Saadeh S, Cammell G, Carey WD, et al. The role of liver biopsy in chronic hepatitis C. *Hepatology*. 2001;33:196-200.
- Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. *Hepatology*. 2002;36:973-977.
- Hui CK, Belaye T, Montegrando K, et al. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. *J Hepatol*. 2003;38:511-517.
- Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. *Lancet*. 2003;362:2095-2100.
- Alberti A, Noventa F, Benvegno L, et al. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. *Ann Intern Med*. 2002;137:961-964.
- Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. *Hum Pathol*. 2001;32:904-909.
- Lagging LM, Westin J, Svensson E, et al. Progression of fibrosis in untreated patients with hepatitis C virus infection. *Liver*. 2002;22:136-144.
- McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. *Gut*. 2004;53:318-321.
- Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. *Gut*. 2004;53:451-455.
- Koukoulis GK. Chronic hepatitis C: grading, staging, and searching for reliable predictors of outcome. *Hum Pathol*. 2001;32:899-903.
- Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B. *Aliment Pharmacol Ther*. 2004;19:25-37.
- Bravo AA, Sheth SG, Chopra S. Liver biopsy. *N Engl J Med*. 2001;344:495-500.
- Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology*. 2003;38:1449-1457.
- Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. *J Hepatol*. 2003;39:239-244.
- Tobkes AI, Nord HJ. Liver biopsy: review of methodology and complications. *Dig Dis*. 1995;13:267-274.
- DeWitt J, LeBlanc J, McHenry L, et al. Endoscopic ultrasound-guided fine needle aspiration cytology of solid liver lesions: a large single-center experience. *Am J Gastroenterol*. 2003;98:1976-1981.
- Kugelmas M. Liver biopsy. *Am J Gastroenterol*. 2004;99:1416-1417.
- Sherlock S, Dooley J. *Diseases of the Liver and Biliary System*. London, England: Blackwell Science; 1997.
- Gilmore IT, Burroughs A, Murray-Lyon IM, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. *Gut*. 1995;36:437-441.
- Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy; a multicentre retrospective study on 68,276 biopsies. *J Hepatol*. 1986;2:165-173.
- Gunneson TJ, Menon KV, Wiesner RH, et al. Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. *Am J Gastroenterol*. 2002;97:1472-1475.

25. Mayoral W, Lewis JH. Percutaneous liver biopsy: what is the current approach? results of a questionnaire survey. *Dig Dis Sci*. 2001;46:118-127.
26. Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. *World J Gastroenterol*. 1999;5:301-304.
27. Lebrech D. Various approaches to obtaining liver tissue: choosing the biopsy technique. *J Hepatol*. 1996;25(suppl 1):20-24.
28. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. *Gut*. 1999;45(suppl 4):IV1-IV11.
29. Robles-Diaz G, Chavez M, Lopez M, et al. Critical analysis of 1263 percutaneous hepatic biopsies carried out over a 12-year period (1970-1981) in the Salvador Zubiran National Institute of Nutrition [in Spanish]. *Rev Gastroenterol Mex*. 1985;50:13-17.
30. McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. *Gastroenterology*. 1990;99:1396-1400.
31. Maharaj B, Bhoora IG. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken. *Postgrad Med J*. 1992;68:964-967.
32. Cadranet JF, Rufat P, Degos F, for the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Practices of liver biopsy in France: results of a prospective nationwide survey. *Hepatology*. 2000;32:477-481.
33. Lindor KD, Bru C, Jorgensen RA, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. *Hepatology*. 1996;23:1079-1083.
34. Younossi ZM, Teran JC, Ganiats TG, et al. Ultrasound-guided liver biopsy for parenchymal liver disease: an economic analysis. *Dig Dis Sci*. 1998;43:46-50.
35. Farrell RJ, Smiddy PF, Pilkington RM, et al. Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. *J Hepatol*. 1999;30:580-587.
36. Papini E, Pacella CM, Rossi Z, et al. A randomized trial of ultrasound-guided anterior subcostal liver biopsy versus the conventional Menghini technique. *J Hepatol*. 1991;13:291-297.
37. Muir AJ, Trotter JF. A survey of current liver biopsy practice patterns. *J Clin Gastroenterol*. 2002;35:86-88.
38. Stotland BR, Lichtenstein GR. Liver biopsy complications and routine ultrasound [editorial]. *Am J Gastroenterol*. 1996;91:1295-1296.
39. Gamble P, Colapinto RF, Stronell RD, et al. Transjugular liver biopsy: a review of 461 biopsies. *Radiology*. 1985;157:589-593.
40. Lebrech D, Goldfarb G, Degott C, et al. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. *Gastroenterology*. 1982;83:338-340.
41. Bull HJ, Gilmore IT, Bradley RD, et al. Experience with transjugular liver biopsy. *Gut*. 1983;24:1057-1060.
42. Bruzzi JF, O'Connell MJ, Thakore H, et al. Transjugular liver biopsy: assessment of safety and efficacy of the Quick-Core biopsy needle. *Abdom Imaging*. 2002;27:711-715.
43. Smith TP, Presson TL, Heneghan MA, et al. Transjugular biopsy of the liver in pediatric and adult patients using an 18-gauge automated core biopsy needle: a retrospective review of 410 consecutive procedures. *AJR Am J Roentgenol*. 2003;180:167-172.
44. McAfee JH, Keeffe EB, Lee RG, et al. Transjugular liver biopsy. *Hepatology*. 1992;15:726-732.
45. Papatheodoridis GV, Patch D, Watkinson A, et al. Transjugular liver biopsy in the 1990s: a 2-year audit. *Aliment Pharmacol Ther*. 1999;13:603-608.
46. Holund B, Poulsen H, Schlichting P. Reproducibility of liver biopsy diagnosis in relation to the size of the specimen. *Scand J Gastroenterol*. 1980;15:329-335.
47. Schlichting P, Holund B, Poulsen H. Liver biopsy in chronic aggressive hepatitis: diagnostic reproducibility in relation to size of specimen. *Scand J Gastroenterol*. 1983;18:27-32.
48. Azzem S, Schiano T, Bodian C, et al. Importance of specimen size inaccurate needle liver biopsy evaluation of patients with chronic hepatitis C. *Hepatology*. 2002;36:345A.
49. Bedossa P, Poynard T, for the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. *Hepatology*. 1996;24:289-293.
50. Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. *Hepatology*. 1998;28:323-331.
51. Gaiani S, Gramantieri L, Venturoli N, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? a prospective study comparing ultrasonography and percutaneous liver biopsy. *J Hepatol*. 1997;27:979-985.
52. ter Borg F, ten Kate FJ, Cuypers HT, et al. A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals. *J Clin Pathol*. 2000;53:541-548.
53. Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. *Br J Haematol*. 1995;89:757-761.
54. Hopper KD, Abendroth CS, Sturtz KW, et al. Blinded comparison of biopsy needles and automated devices in vitro, 1: biopsy of diffuse hepatic disease. *AJR Am J Roentgenol*. 1993;161:1293-1297.
55. Colombo M, Del Ninno E, de Franchis R, et al. Ultrasound-assisted percutaneous liver biopsy: superiority of the Tru-Cut over the Menghini needle for diagnosis of cirrhosis. *Gastroenterology*. 1988;95:487-489.
56. Rocken C, Meier H, Klauck S, et al. Large-needle biopsy versus thin-needle biopsy in diagnostic pathology of liver diseases. *Liver*. 2001;21:391-397.
57. Brunetti E, Silini E, Pistorio A, et al. Coarse vs fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis. *J Hepatol*. 2004;40:501-506.
58. Petz D, Klauck S, Rohl FW, et al. Feasibility of histological grading and staging of chronic viral hepatitis using specimens obtained by thin-needle biopsy. *Virchows Arch*. 2003;442:238-244.
59. Goldner F. Comparison of the Menghini, Klatskin and Tru-Cut needles in diagnosing cirrhosis. *J Clin Gastroenterol*. 1979;1:229-231.
60. Chau TN, Tong SW, Li TM, et al. Transjugular liver biopsy with an automated Trucut-type needle: comparative study with percutaneous liver biopsy. *Eur J Gastroenterol Hepatol*. 2002;14:19-24.
61. Vargas-Tank L, Martinez V, Jiron MI, et al. Tru-Cut and Menghini needles: different yield in the histological diagnosis of liver disease. *Liver*. 1985;5:178-181.
62. Torp-Pedersen S, Vyberg M, Smith E, et al. Surecut 0.6 mm liver biopsy in the diagnosis of cirrhosis. *Liver*. 1990;10:217-220.
63. Caturelli E, Giacobbe A, Facciorusso D, et al. Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site. *Am J Gastroenterol*. 1996;91:1318-1321.

64. Chevallier P, Ruitort F, Denys A, et al. Influence of operator experience on performance of ultrasound-guided percutaneous liver biopsy. *Eur Radiol.* 2004;14:2086-2091.
65. Flamm S, Upton M, Parker R, et al. Histopathologic heterogeneity in chronic hepatitis C virus infection: are two liver biopsy specimens better than one? *Hepatology.* 1995;22:A15.
66. Siddique I, El Naga HA, Mada JP, et al. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. *Scand J Gastroenterol.* 2003;38:427-432.
67. Kim Y, Groman A, Shah A, et al. Ultrasound guided and blind liver biopsies at a tertiary referral center: a retrospective comparison of outcomes and complications [abstract]. *Am J Gastroenterol.* 2004;99(suppl):S80.
68. Bateson MC, Hopwood D, Duguid HL, et al. A comparative trial of liver biopsy needles. *J Clin Pathol.* 1980;33:131-133.
69. Meng HC, Lin HC, Huang CC, et al. Transjugular liver biopsy: comparison with percutaneous liver biopsy. *J Gastroenterol Hepatol.* 1994;9:457-461.
70. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. *Lancet.* 1986;1:523-525.
71. Gurakar A, Balkan M, Fagioli S, et al. Experience with percutaneous liver biopsies using two different needles: a 14 G Trucut needle or a 15 G needle gun. *Hepatology.* 1993;16:A911.
72. Spirchez Z, Fayad E, Albu S, et al. Comparison of two needles, the Surecut (18G) versus the biopsy gun (18G) in percutaneous liver biopsy. *Hepatology.* 1999;30:A1279.
73. Regan J, Mihalov M, Limjoko A, et al. Transjugular liver biopsy: evaluation and comparison with percutaneous biopsy. *Hepatology.* 1997;26:281A.
74. Judmaier G, Prior C, Klimpfinger M, et al. Is percutaneous liver biopsy using the Trucut (Travenol) needle superior to Menghini puncture [in German]? *Z Gastroenterol.* 1989;27:657-661.
75. Steadman C, Teague C, Harper J, et al. Transjugular liver biopsy: an Australian experience. *Aust N Z J Med.* 1988;18:836-840.
76. Camma C, Di MV, Lo IO, et al. Long-term course of interferon-treated chronic hepatitis C. *J Hepatol.* 1998;28:531-537.
77. Fontana RJ, Israel J, LeClair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. *Hepatology.* 2000;31:730-736.
78. Poynard T, Marcellin P, Bissery A, et al. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. *J Viral Hepat.* 2003;10:197-204.
79. Kaserer K, Fiedler R, Steindl P, et al. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. *Histopathology.* 1998;32:454-461.
80. Payen JL, Izopet J, Galindo-Migeot V, et al, for the Le Groupe D'etude et De Traitement du Virus De L'hepatite C (GetVhc). Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. *Hepatology.* 1998;28:1680-1686.
81. Everson GT, Jensen DM, Craig JR, et al. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. *Hepatology.* 1999;30:271-276.
82. Alri L, Duffaut M, Selves J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. *J Hepatol.* 2001;35:272-278.
83. Bjoro K, Bell H, Myrvang B, et al. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection: a randomized multicentre study. *Scand J Gastroenterol.* 2002;37:344-349.
84. Bjoro K, Bell H, Hellum KB, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. *Scand J Gastroenterol.* 2002;37:226-232.
85. Tong MJ, Reddy KR, Lee WM, et al, for the Consensus Interferon Study Group. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. *Hepatology.* 1997;26:747-754.
86. Bonkovsky HL, Stefanczyk D, McNeal K, et al. Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. *Dig Dis Sci.* 2001;46:2051-2059.
87. Engler S, Flechtenmacher C, Wiedemann KH, et al. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. *J Viral Hepat.* 2004;11:60-68.
88. Casanovas-Taltavull T, Baliellis C, Benasco C, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. *Am J Gastroenterol.* 2001;96:1170-1177.
89. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. *J Hepatol.* 2003;38:818-826.
90. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med.* 1999;341:1256-1263.
91. Honkoop P, de Man RA, Zondervan PE, et al. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. *Liver.* 1997;17:103-106.
92. Fanning L, Loane J, Kenny-Walsh E, et al. Tissue viral load variability in chronic hepatitis C. *Am J Gastroenterol.* 2001;96:3384-3389.
93. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol.* 2002;97:2614-2618.
94. Persico M, Palmentieri B, Vecchione R, et al. Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy [letter]. *Am J Gastroenterol.* 2002;97:491-492.
95. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology.* 1994;20(1 pt 1):15-20.
96. Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. *J Hepatol.* 1996;25:649-654.
97. Westin J, Lagging LM, Wejstal R, et al. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. *Liver.* 1999;19:183-187.
98. Gronbaek K, Christensen PB, Hamilton-Dutoit S, et al. Interobserver variation in interpretation of serial liver biopsies from patients with chronic hepatitis C. *J Viral Hepat.* 2002;9:443-449.

99. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. *J Hepatol*. 2003;38:223-229.
100. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. *Hepatology*. 2005;41:257-264.
101. Sawyerr AM, McCormick PA, Tennyson GS, et al. A comparison of transjugular and plugged-percutaneous liver biopsy in patients with impaired coagulation. *J Hepatol*. 1993;17:81-85.
102. Choo SW, Do YS, Park KB, et al. Transjugular liver biopsy: modified Ross transseptal needle versus Quick-Core biopsy needle. *Abdom Imaging*. 2000;25:483-485.
103. DiMichele DM, Mirani G, Wilfredo CP, et al. Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. *Haemophilia*. 2003;9:613-618.
104. Kardache M, Soyer P, Boudiaf M, et al. Transjugular liver biopsy with an automated device. *Radiology*. 1997;204:369-372.
105. De Hoyos A, Loredó ML, Martínez-Ríos MA, et al. Transjugular liver biopsy in 52 patients with an automated Trucut-type needle. *Dig Dis Sci*. 1999;44:177-180.
106. Elsharkawy A, Austin A, Ryder S. Clinical impact of transjugular liver biopsies in a non-transplant center. *Hepatology*. 2002;36:728A.
107. Gorriz E, Reyes R, Lóbrano MB, et al. Transjugular liver biopsy: a review of 77 biopsies using a spring-propelled cutting needle (biopsy gun). *Cardiovasc Intervent Radiol*. 1996;19:442-445.
108. Little AF, Zajko AB, Orons PD. Transjugular liver biopsy: a prospective study in 43 patients with the Quick-Core biopsy needle. *J Vasc Interv Radiol*. 1996;7:127-131.
109. Cholongitas E, Quaglia A, Samonakis D, et al. Transjugular liver biopsy: is it effective for accurate histological interpretation [abstract]? *Gut*. 2005;54:A26.
110. Andriulli A, Annese V, Facciorusso D, et al. First do no harm: power, oppression, and violence of liver biopsy [letter]. *Gastroenterology*. 2003;125:272-273.
111. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase–alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus–related chronic liver disease. *Arch Intern Med*. 2003;163:218-224.
112. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*. 2003;38:518-526.
113. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. *Am J Gastroenterol*. 2004;99:1160-1174.
114. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology*. 2002;36:986-992.
115. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. *Hepatology*. 2005;42:282-292.
116. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet*. 2001;357:1069-1075.
117. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. *Hepatology*. 2003;38:481-492.
118. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? *Hepatology*. 2003;37:972-974.
119. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology*. 2005;128:343-350.
120. Chalmers RJ, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. *Br J Dermatol*. 2005;152:444-450.
121. Hui AY, Chan HL, Wong VW, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. *Am J Gastroenterol*. 2005;100:616-623.
122. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. *Gastroenterology*. 2004;127:1704-1713.
123. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. *Clin Chem*. 2003;49:450-454.
124. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology*. 2005;41:48-54.
125. Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. *Hepatology*. 2005;42:838-845.
126. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. *Am J Gastroenterol*. 2005;100:1970-1980.
127. Demetris AJ, Ruppert K. Pathologist's perspective on liver needle biopsy size? *J Hepatol*. 2003;39:275-277.

First and Only FDA Cleared Digital Cytology System

Genius™ Cervical AI

Genius™ Review Station

Genius™ Digital Imager



Empower Your Genius With Ours

Make a Greater Impact on Cervical Cancer
with the Advanced Technology of the
Genius™ Digital Diagnostics System



Click or Scan
to discover more

ADS-04159-001 Rev 001 © 2024 Hologic, Inc. All rights reserved. Hologic, Genius, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, podcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your Hologic representative or write to diagnostic.solutions@hologic.com.

genius™
DIGITAL DIAGNOSTICS